*ST Mingde disclosed its 2026 interim report on the evening of August 27. In the first half, it achieved operating revenue of 141 million yuan, up 1.54% year on year, while net profit attributable to the parent company was a loss of 21.8676 million yuan. Pressure on the profit side mainly came from reduced government subsidies, higher credit impairment losses, and lower wealth-management income. Together, these three items reduced total profit by more than 40 million yuan year on year. Excluding those effects, the company would have posted a profit of 16 million to 24 million yuan in the first half. The company focuses on critical care and infectious disease diagnostics, and its product portfolio continues to expand. By the end of June, it had obtained 260 product registration certificates and 77 EU CE certifications. Overseas revenue reached 33.512 million yuan, up 40.16% year on year, with its share of revenue rising to 23.70%. On the external growth front, the company acquired 100% equity in Bikar for 190 million yuan, and the industrial and commercial registration change was completed on August 14. Bikar's revenue and profit have not yet been included in this interim report, but the counterparty Blue Sail Medical has committed that Bikar's cumulative net profit from 2026 to 2028 will be no less than 65 million yuan. As the deal closes, the company's business extends from in-hospital diagnostics to out-of-hospital protection and emergency care, and the incremental performance is expected to be gradually released.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A*ST Mingde completed its 190 million yuan acquisition of Bikar, extending its business into out-of-hospital protection and emergency care with expected incremental performance.
Blue Sail Medical Co LtdBlue Sail Medical is the counterparty selling Bikar for 190 million yuan and guaranteeing Bikar's cumulative net profit of no less than 65 million yuan from 2026-2028.
